Management of Hyperglycemia in Type 2 Diabetes: A Summary of New Consensus Report from the American Diabetes Association and the European Association for the Study of Diabetes in 2018.

Kim,  Jeong Mi; Kim,  Sang Soo

doi:2019.20.1.6

J Korean Diabetes > Volume 20(1); 2019 > Article

Statement

The Journal of Korean Diabetes 2019;20(1):6-9.
DOI: https://doi.org/10.4093/jkd.2019.20.1.6 Published online April 4, 2019.

제2형 당뇨병 환자의 혈당 관리: 2018년 미국/유럽 당뇨병학회 합의안 요약

김정미, 김상수

Management of Hyperglycemia in Type 2 Diabetes: A Summary of New Consensus Report from the American Diabetes Association and the European Association for the Study of Diabetes in 2018.

Jeong Mi Kim, Sang Soo Kim

Division of Endocrinology and Metabolism, Department of Internal Medicine, and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea. drsskim7@gmail.com

Abstract

In 2018, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a consensus recommendation on management of hyperglycemia. This consensus report emphasized the need for patient-centered management considering multimorbidity and individual patient preferences and barriers. Patients with type 2 diabetes with established atherosclerotic cardiovascular disease who fail to control blood glucose with the initial glucose-lowering medication are recommended a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist. For patients with chronic kidney disease and heart failure, SGLT2 inhibitors are recommended. In patients who need an injectable medication, GLP-1 receptor agonists are the preferred choice over insulin. In this section, we summarize “Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).”

Key Words: Atherosclerosis, Cardiovascular disease, Diabetes mellitus, type 2, Hyperglycemia, Patient-centered care